CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-2.22%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Amazon
AMZN
|
$8.41M |
| 3 |
Microsoft
MSFT
|
$6.53M |
| 4 |
Analog Devices
ADI
|
$4.63M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$3.68M |
Top Sells
| 1 |
iShares Silver Trust
SLV
|
$7.9M |
| 2 |
ProShares Ultra Gold
UGL
|
$7.89M |
| 3 |
Arista Networks
ANET
|
$6.7M |
| 4 |
Gilead Sciences
GILD
|
$5.26M |
| 5 |
TSMC
TSM
|
$3.61M |
Sector Composition
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Zai Lab
ZLAB
$3.42B
| $453K | 0.04% |
12,544
+1,483
| +13% | +$53.6K |
|
252
NewAmsterdam Pharma
NAMS
$3.04B
| $451K | 0.04% |
22,028
+2,439
| +12% | +$49.9K |
|
253
Vericel Corp
VCEL
$1.72B
| $447K | 0.04% |
10,023
-443
| -4% | -$19.8K |
|
254
Mirum Pharmaceuticals
MIRM
$3.82B
| $443K | 0.04% |
9,831
-348
| -3% | -$15.7K |
|
255
ImmunityBio
IBRX
$2.27B
| $441K | 0.04% |
146,458
-1,296
| -0.9% | -$3.9K |
|
256
Diageo
DEO
$61.3B
| $438K | 0.04% |
4,117
| – | – |
|
257
Deckers Outdoor
DECK
$17.9B
| $437K | 0.04% |
3,908
+3,758
| +2,505% | +$420K |
|
258
Wave Life Sciences
WVE
$1.32B
| $424K | 0.04% |
52,520
-1,747
| -3% | -$14.1K |
|
259
ON Semiconductor
ON
$20.1B
| $424K | 0.04% |
10,409
+3,480
| +50% | +$142K |
|
260
Recursion Pharmaceuticals
RXRX
$2.01B
| $419K | 0.04% |
79,245
-1,698
| -2% | -$8.98K |
|
261
Edgewise Therapeutics
EWTX
$1.64B
| $418K | 0.04% |
18,993
-1,084
| -5% | -$23.8K |
|
262
Ligand Pharmaceuticals
LGND
$3.25B
| $406K | 0.04% |
3,862
-145
| -4% | -$15.2K |
|
263
Denali Therapeutics
DNLI
$2.26B
| $396K | 0.04% |
29,128
-1,389
| -5% | -$18.9K |
|
264
Tarsus Pharmaceuticals
TARS
$2.43B
| $395K | 0.04% |
7,698
-408
| -5% | -$21K |
|
265
NovoCure
NVCR
$1.37B
| $393K | 0.04% |
22,047
-896
| -4% | -$16K |
|
266
Harmony Biosciences
HRMY
$2.07B
| $382K | 0.04% |
11,503
-590
| -5% | -$19.6K |
|
267
AutoZone
AZO
$70.6B
| $381K | 0.04% |
100
| – | – |
|
268
Huazhu Hotels Group
HTHT
$11.5B
| $378K | 0.04% |
10,200
+10,000
| +5,000% | +$370K |
|
269
CG Oncology
CGON
$2.52B
| $374K | 0.03% |
15,270
+930
| +6% | +$22.8K |
|
270
Arcutis Biotherapeutics
ARQT
$2.06B
| $372K | 0.03% |
23,797
-1,021
| -4% | -$16K |
|
271
Kymera Therapeutics
KYMR
$3.11B
| $357K | 0.03% |
13,027
-706
| -5% | -$19.3K |
|
|
272
iShares Silver Trust
SLV
$20.1B
| $353K | 0.03% |
11,400
-255,000
| -96% | -$7.9M |
|
273
Arm
ARM
$146B
| $345K | 0.03% |
3,234
-3,650
| -53% | -$390K |
|
274
Disc Medicine
IRON
$2.11B
| $344K | 0.03% |
6,934
+624
| +10% | +$31K |
|
275
Apogee Therapeutics
APGE
$2.26B
| $337K | 0.03% |
9,032
-515
| -5% | -$19.2K |
|